Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography
Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself
Disorders of carnitine transport and the carnitine cycle
Research shows that large portion sizes often lead to consuming more calories despite not being hungry
doi: 10.3390/ijms17111868 108 JiangNZhaoHHanYLiLXiongSZengLet al
Eli Lillys weight-loss pill, orforglipron, has been submitted to the FDA and the company says it expects approval by the spring
US$ 28.67
US$ 25.23
US$ 25.78
